About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Tg(KLKB1-cre/ERT2)1Pcn
transgene insertion 1, Pierre Chambon
MGI:3775927
Summary 2 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Artm3.1(AR)Ska/Y
Tg(KLKB1-cre/ERT2)1Pcn/0 		involves: C57BL/6 * C57BL/6J * CBA MGI:4946829
cn2
 		Artm3.1(AR)Ska/Y
Tg(KLKB1-cre/ERT2)1Pcn/0
Tg(TRAMP)8247Ng/0 		involves: C57BL/6 * C57BL/6J * CBA MGI:4946830


Genotype
MGI:4946829
cn1
Allelic
Composition		 Artm3.1(AR)Ska/Y
Tg(KLKB1-cre/ERT2)1Pcn/0
Genetic
Background		 involves: C57BL/6 * C57BL/6J * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Artm3.1(AR)Ska mutation (0 available); any Ar mutation (23 available)
Tg(KLKB1-cre/ERT2)1Pcn mutation (1 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
reproductive system
increased prostate gland ventral lobe weight ( J:170092 )
• at 16 weeks, tamoxifen-treated mice exhibit increased ventral prostate weight compared with Artm3.1(AR)Ska hemizygous males
increased prostate gland weight ( J:170092 )
• at 16 weeks, tamoxifen-treated mice exhibit increased total prostate weight compared with Artm3.1(AR)Ska hemizygous males
abnormal prostate gland physiology ( J:170092 )
• tamoxifen-treated mice exhibit increased proliferation of prostate cells compared to in Artm3.1(AR)Ska hemizygous males
• tamoxifen-treated mice exhibit increased growth in response to androgen antagonist and estrogen unlike Artm3.1(AR)Ska hemizygous males
reduced fertility ( J:170092 )
• tamoxifen-treated male mice exhibit reduced reproductive activity compared with wild-type mice

homeostasis/metabolism
increased circulating testosterone level ( J:170092 )
• in tamoxifen-treated male mice

endocrine/exocrine glands
increased prostate gland ventral lobe weight ( J:170092 )
• at 16 weeks, tamoxifen-treated mice exhibit increased ventral prostate weight compared with Artm3.1(AR)Ska hemizygous males
increased prostate gland weight ( J:170092 )
• at 16 weeks, tamoxifen-treated mice exhibit increased total prostate weight compared with Artm3.1(AR)Ska hemizygous males
abnormal prostate gland physiology ( J:170092 )
• tamoxifen-treated mice exhibit increased proliferation of prostate cells compared to in Artm3.1(AR)Ska hemizygous males
• tamoxifen-treated mice exhibit increased growth in response to androgen antagonist and estrogen unlike Artm3.1(AR)Ska hemizygous males




Genotype
MGI:4946830
cn2
Allelic
Composition		 Artm3.1(AR)Ska/Y
Tg(KLKB1-cre/ERT2)1Pcn/0
Tg(TRAMP)8247Ng/0
Genetic
Background		 involves: C57BL/6 * C57BL/6J * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Artm3.1(AR)Ska mutation (0 available); any Ar mutation (23 available)
Tg(KLKB1-cre/ERT2)1Pcn mutation (1 available)
Tg(TRAMP)8247Ng mutation (1 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:170092 )
• tamoxifen-treated mice die at around 36 weeks of age compared with 48 weeks for Artm3.1(AR)Ska Tg(TRAMP)8247Ng hemizygous males

neoplasm
increased prostate gland tumor incidence ( J:170092 )
• tamoxifen-treated mice exhibit earlier onset of prostate tumor growth compared with Artm3.1(AR)Ska Tg(TRAMP)8247Ng hemizygous males
abnormal tumor morphology ( J:170092 )
• castration of nude mice transplanted with tumors from tamoxifen-treated mice attenuates tumor growth more than in Artm3.1(AR)Ska Tg(TRAMP)8247Ng hemizygous males
increased tumor growth/size ( J:170092 )
• prostate tumors from tamoxifen-treated mice transplanted into nude mice exhibit increased tumor growth compared with tumors from Artm3.1(AR)Ska Tg(TRAMP)8247Ng hemizygous males
decreased tumor latency ( J:170092 )
• tamoxifen-treated mice exhibit earlier onset of prostate tumor growth compared with Artm3.1(AR)Ska Tg(TRAMP)8247Ng hemizygous males

reproductive system
increased prostate gland tumor incidence ( J:170092 )
• tamoxifen-treated mice exhibit earlier onset of prostate tumor growth compared with Artm3.1(AR)Ska Tg(TRAMP)8247Ng hemizygous males

endocrine/exocrine glands
increased prostate gland tumor incidence ( J:170092 )
• tamoxifen-treated mice exhibit earlier onset of prostate tumor growth compared with Artm3.1(AR)Ska Tg(TRAMP)8247Ng hemizygous males




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/12/2024
MGI 6.24 		The Jackson Laboratory